Premium Brand STROMUSC Equipoise(Boldenolone Undecylenate)600mg/ml For Bodybuilding CAS:13103-34-9
Boldenone undecylenate occupies a peculiar position in the anabolic landscape. It was never designed for human use. Developed in the 1960s as a veterinary injectable for horses, it found its way into bodybuilding through the back door and never left. The 600mg/ml formulation represents a specific engineering challenge and a specific user experience that differs meaningfully from the standard 200mg/ml preparations most people encounter.
What It Is
Boldenone undecylenate is a testosterone analog with one structural modification: a double bond at the C1-C2 position on the A-ring. That single change alters the compound's behavior in ways that matter. It reduces aromatization to estradiol to roughly half the rate of testosterone, and it also produces a metabolite-1,4-dienedione-that acts as a mild aromatase inhibitor in its own right. The result is a compound that builds lean tissue without the estrogenic bloat that defines a straight testosterone cycle.
The undecylenate ester is what gives the drug its pharmacokinetic character. Undecylenic acid is an eleven-carbon fatty acid chain. When esterified to the 17-beta hydroxyl group of boldenone, it creates a depot that hydrolyzes slowly after intramuscular injection. The ester weight is substantial: only about 61mg of active boldenone base exists per 100mg of the esterified compound. This means a 600mg injection delivers roughly 366mg of actual boldenone. That is not a trivial distinction, and it explains why Equipoise is typically dosed higher than compounds with lighter esters.
The 600mg/ml Concentration Problem
Standard Equipoise preparations are 200mg/ml in sesame oil. Pushing the concentration to 600mg/ml is not simply a matter of dissolving more powder. The undecylenate ester is extremely lipophilic-it is practically insoluble in water and requires nonpolar solvents to hold at high concentrations. At 600mg/ml, formulators typically resort to solvents like guaiacol or high ratios of benzyl benzoate, and the resulting solution is viscous and prone to causing post-injection pain.
User reports on this specific concentration are mixed but instructive. One experienced user noted that "600mg in one jab is enough to get PIP" even with well-made products. Another reported the opposite-"no pip at all" after three weeks of use. This variability likely reflects differences in formulation quality, injection technique, and individual tissue response rather than any consistent property of the molecule itself. The practical takeaway is that 600mg/ml is a concentration that demands careful technique: warm the vial, inject slowly, and rotate sites.
Why the Compound Works the Way It Does
Boldenone's anabolic rating sits at roughly 100-equal to testosterone-while its androgenic rating is approximately 50. This favorable ratio means it promotes nitrogen retention and protein synthesis with less aggression toward the prostate, skin, and hair follicles. The mechanism is straightforward androgen receptor binding, but the downstream effects are what users actually notice.
The most distinctive pharmacological feature is erythropoietin stimulation. Boldenone is a potent driver of EPO release from the kidneys, raising red blood cell mass and oxygen-carrying capacity to a degree that exceeds most other anabolic steroids at comparable doses. This is the source of the endurance boost and the pronounced vascularity that EQ is known for. It is also the compound's primary health liability: hematocrit can climb past 54% by week ten at 500-600mg weekly, at which point therapeutic blood donation becomes non-negotiable.
There is also the estrogen question, which is more complicated than most profiles admit. Approximately half of users experience noticeable downward estrogen pressure from boldenone, requiring either reduced AI dosing or an increased testosterone-to-EQ ratio to avoid low-estrogen symptoms like joint pain and flat mood. The other half do not experience this effect to a significant degree. This split is not well understood, but it means that anyone running EQ for the first time should start with a conservative testosterone ratio and adjust based on bloodwork rather than assumption.
Dosage and Cycle Structure
Equipoise is not a short-cycle compound. The undecylenate ester's half-life of approximately 14 days means blood levels build slowly and plateau somewhere between weeks four and six. Users consistently report that the compound "peaks" in terms of visible effects-vascularity, fullness, appetite-between weeks ten and sixteen. Running EQ for less than twelve weeks is generally considered a waste of both money and injection sites.
For a first-time user, a reasonable starting point is 400-500mg per week, split into two injections to smooth plasma levels and reduce injection volume per site. More experienced users often push to 600-800mg weekly, though the returns diminish and the hematocrit risk rises proportionally. The 600mg/ml concentration makes higher doses more convenient from an injection volume perspective: 1ml per week delivers a full 600mg dose, whereas the same dose would require three separate injections with 200mg/ml product.
Stacking is almost universal. Testosterone should remain the base at a minimum of 200-300mg weekly to preserve libido and androgen signaling. A 2:1 testosterone-to-EQ ratio is a sensible starting point, adjustable based on how the individual responds to EQ's estrogen-lowering tendencies. EQ pairs well with compounds that do not further suppress estrogen-masteron, anavar, or low-dose trenbolone in advanced protocols-but stacking it with another strongly aromatizing compound can create unpredictable estrogen management challenges.
Half-Life and Detection Window
The undecylenate ester's half-life is consistently cited at approximately 14 days in both veterinary and human-use literature. This long half-life has practical implications beyond cycle planning. Detection times for boldenone metabolites extend well beyond the active window: research in cattle detected 17-beta-boldenone up to 92 days after administration, and equine studies found boldenone sulfate in urine for up to 42 days following a single therapeutic dose. For anyone subject to testing, boldenone is among the least forgiving compounds available.
The long half-life also dictates the timing of post-cycle therapy. This is where many users make their most consequential error.
PCT Timing: The Non-Negotiable Variable
The conventional wisdom about PCT timing-wait two weeks after the last injection-does not apply to Equipoise. With a 14-16 day half-life, boldenone remains active in the system for six to eight weeks after the final injection. Starting a SERM protocol too early is not merely ineffective; it is wasteful and potentially counterproductive, because the suppressive pressure from residual boldenone will continue to suppress the HPTA even as the SERM attempts to restart it.
The evidence-based approach is to wait a minimum of five weeks after the last EQ injection before starting PCT, and many practitioners recommend six. Bloodwork should confirm that LH and FSH are beginning to recover before committing to the protocol. A standard moderate-cycle PCT after an EQ run looks like this: clomiphene at 100mg daily for the first ten days, then 50mg daily for another ten days, combined with tamoxifen at 40mg daily for two weeks followed by 20mg daily for two more weeks. HCG at 2500 IU weekly for two weeks is optional but can accelerate testicular recovery if shrinkage is a concern.
The critical point is patience. Users who feel fine three weeks after their last pin and start PCT are almost certainly suppressing themselves with residual boldenone. The compound does not clear quickly, and the HPTA will not restart until it does.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
Boldane, Equipoise, Parenabol, Vebonol |
|
CAS |
13103-34-9 |
|
Molar mass |
452.679 |
|
Formula |
C30H44O3 |
|
Purity |
Above 98% |
|
Capacity/Bottle |
600mg/ml,10ml/bottle |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785
What This Compound Actually Delivers
Equipoise 600mg/ml is not a mass monster. It does not produce the rapid, dramatic gains of Dianabol or the raw strength of trenbolone. What it produces, over a sixteen-week window, is a slow accumulation of lean tissue that looks earned rather than inflated. The vascularity becomes visible around week twelve. The appetite increase-a genuine pharmacological effect, not a placebo-makes it easier to eat in a surplus. The endurance boost from elevated red blood cells lets you train longer and recover faster.
The trade-off is that none of this happens quickly, and the compound asks a lot in return: frequent bloodwork, hematocrit management, careful estrogen monitoring, and a PCT protocol that requires more patience than most users initially expect. The 600mg/ml concentration simply makes the logistics of running a proper dose more convenient. It does not change what the molecule does or who it suits.
Hot Tags: premium brand stromusc equipoise(boldenolone undecylenate)600mg/ml for bodybuilding cas:13103-34-9, China premium brand stromusc equipoise(boldenolone undecylenate)600mg/ml for bodybuilding cas:13103-34-9 manufacturers, suppliers, factory
